PharmaEngine, Inc.

PharmaEngine Inc. (Taipei Exchange: stock code 4162.TWO) began operations in 2003, is a commercial stage pharmaceutical company dedicated to developing medicines for cancer patients. We are currently focusing on precision oncology related to DNA damage response (DDR) pathways. PEP07, an orally bioavailable small molecule CHK1 inhibitor with brain penetrating properties, is currently in Phase 1 clinical studies for Acute Myeloid Leukemia (AML), Mantle Cell Lymphoma (MCL), or advanced/metastatic solid tumors. Our preclinical pipeline includes other targets in the DDR pathways aiming to provide synergy when in combinations with chemo/radiation therapies or with other precision oncology medicines. In the past, PharmaEngine successfully developed and out-licensed its first commercial product, ONIVYDE (liposomal irinotecan), for the treatment of metastatic pancreatic adenocarcinoma. It is also responsible for the commercialization of ONIVYDE in Taiwan. We strongly believe in building a sustainable business and work environment with our six core values. We encourage employees to have “Sense of Urgency” and adopt “Critical Thinking” when facing dynamic environments and challenges that require rapid responses. We wish to build a work environment with “Diversity” and a space for “Continuous Learning and Growth” as we believe inclusivity and room for growth are crucial to employee welfare. “Teamwork” is crucial in new drug development and we hope through considerate communication and sharing, each member can utilize their specialties and feel valued. Lastly, we put great emphasis on helping each member achieve their individual “Work and Life Balance” in different stages of life. For more information, please visit our company website.